Table S1.
Patients (n) | AGR2 mRNA | AGR3 mRNA | |
---|---|---|---|
Histological grade | |||
G1 | 26 | 0.166a | 0.037a |
G2 | 33 | ||
G3 | 34 | ||
Tumor size | |||
pT1 | 35 | 0.774a | 0.990a |
pT2 | 50 | ||
pT3 + pT4 | 8 | ||
Nodal status | |||
Negative | 37 | 0.822b | 0.541b |
Positive | 52 | ||
ER status | |||
Negative | 17 | 0.081b | <0.001b |
Positive | 76 | ||
PR status | |||
Negative | 19 | 0.124b | <0.001b |
Positive | 73 | ||
Her2/neu status | |||
Negative | 57 | 0.364b | 0.603b |
Positive | 36 | ||
Ki-67 | |||
<15% | 44 | 0.169b | 0.494b |
≥15% | 48 |
Notes:
Determination of P-level using Kruskal–Wallis analysis of variance.
Determination of P-level using Mann–Whitney U-test.
Abbreviations: AGR, anterior gradient protein; ER, estrogen receptor; PR, progesterone receptor; Her2/neu, human epidermal growth factor receptor 2.